<DOC>
	<DOCNO>NCT02589301</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics ( relative bioavailability ) pharmacodynamics , single subcutaneous application , healthy volunteer sex , pegfilgrastim formulation , produce Eurofarma Laboratorios S/A Neulastim® ( reference formulation ) , market Produtos Roche Químicos e Farmacêuticos S/A . In addition , pharmacodynamics comparison perform , change absolute neutrophil count leukogram perform time pharmacokinetics analysis collection CD34+ cell count peripheral blood timepoints 0:00 , 96:00 384:00 hour .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<criteria>Body mass index equal higher 18.5 equal less 29.9 kg/m2 . The volunteer good health condition clinically significant disease , per medical opinion , accord Medical History , measurements Blood Pressure , Heart Rate Temperature , Physical Exam , Electrocardiogram , complementary Laboratorial Exams . Able understand study nature objective , include risk adverse event intend cooperate researcher act accord whole study requirement , confirm signature Informed Consent Form . The volunteer know hypersensitivity study drug product chemicallyrelated compound . History presence hepatic gastrointestinal disease condition interfere drug product absorption , distribution , excretion metabolism . Use maintenance therapy drug product , except oral contraceptive pill . History hepatic , renal , pulmonary , gastrointestinal , neurological , hematological , psychiatric , cardiologic allergic disease etiology require pharmacological treatment consider clinically relevant researcher . Electrocardiographic finding recommend researcher participate study . Results complementary laboratorial exam outside value consider normal accord protocol rule , unless consider nonclinically significant researcher . Smoking . Daily intake 5 cup tea coffee . History drug alcohol abuse . Use regular medication within 2 week precede begin study use medication one week start study . Hospital admission reason 8 week start first study treatment period . Treatment last 3 month start study treatment drug product know welldefined toxic potential large organ . Participation pharmacokinetics study collection 300 mL blood intake experimental drug product last six month start study treatment . Donation loss 450 mL blood last three month precede study donation 1500 mL blood last 12 month start study treatment . Reagent result urine βHCG exam , perform female volunteer . Positive result urine test detection abuse drug . Result high 0.1 mg/L ethylometer test . Any condition prevent participation study per researcher 's opinion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>